A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies

被引：1
|
作者：
Shah, Nirav N. [1 ]
Krishnan, Amrita Y. [2 ]
Shah, Nina D. [3 ]
Burke, John M. [4 ]
Melear, Jason M. [5 ]
Spira, Alexander I. [6 ]
Kaufman, Jonathan L. [7 ]
Cohen, Jonathon B. [7 ]
Niesvizky, Ruben [8 ]
Popplewell, Leslie L. [2 ]
Chhabra, Saurabh [1 ]
Sharman, Jeff P. [9 ]
Martin, Thomas G. [3 ]
Matheny, Shannon L. [10 ]
Leonard, John P. [8 ]
Molina, Arturo [10 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Rocky Mt Canc Centers, Aurora, CO USA
[5] Texas Oncol, Austin, TX USA
[6] Virginia Canc Specialists, Fairfax, VA USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[9] Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[10] Sutro Biopharma, San Francisco, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT104
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Nobuaki Matsubara
    Shota Kusuhara
    Noboru Yamamoto
    Kazuki Sudo
    Masahiko Yanagita
    Kosho Murayama
    Hisashi Kawasumi
    Deanna L. Russell
    Da Yin
    Toshio Shimizu
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 341 - 352
  • [22] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [23] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Matsubara, Nobuaki
    Kusuhara, Shota
    Yamamoto, Noboru
    Sudo, Kazuki
    Yanagita, Masahiko
    Murayama, Kosho
    Kawasumi, Hisashi
    Russell, Deanna L.
    Yin, Da
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 341 - 352
  • [24] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Jones, Jeffrey A.
    Benson, Don M., Jr.
    Flynn, Joseph M.
    Porcu, Pierluigi
    Lustberg, Mark E.
    Phelps, Mitchell
    Poi, Ming
    Chung, Diana
    Quinion, Carl
    Byrd, John C.
    Wegener, William
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2011, 118 (21) : 1584 - 1584
  • [25] An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
    RA Eisenberg
    S Khan
    J Stansberry
    D Tsai
    S Kolasinski
    E Rieder
    B Kotzin
    RJ Looney
    C Strieber
    D Albert
    Arthritis Res Ther, 6 (Suppl 3):
  • [26] Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial
    Zhu, Jun
    Song, Yuqin
    Li, Jianyong
    Zhou, Keshu
    Ke, Xiaoyan
    Cai, Zhen
    Zhang, Huilai
    Yao, Tingting
    Xia, Zhen
    Wang, Yiqiu
    Lai, Peiqiong
    Liu, Xiaofeng
    BLOOD, 2022, 140 : 6496 - 6497
  • [27] A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies
    Tariq, Bilal
    Ou, Ying C.
    Stern, Jennifer C.
    Mundra, Vaibhav
    Doo, Nicole Wong
    Walker, Patricia
    Lewis, Katharine L.
    Lin, Chester
    Novotny, William
    Sahasranaman, Srikumar
    Opat, Stephen
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 329 - 338
  • [28] An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors
    Li, Kaiwen
    Shi, Yehui
    Wu, Junyan
    Zhou, Liyan
    Ye, Suiwen
    Lai, Xiuping
    Huang, Robert
    Teng, Yan
    Yu, Jiangang
    Chai, Xiaoyan
    Huang, Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors
    Liu, D.
    Shen, L.
    Sun, Y.
    Li, N.
    Marathe, O.
    Huang, R.
    Shao, J.
    Xu, M.
    Pan, B.
    Pan, F.
    Gao, S.
    Gong, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S512 - S513
  • [30] A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
    Kurzrock, Razelle
    Voorhees, Peter M.
    Casper, Corey
    Furman, Richard R.
    Fayad, Luis
    Lonial, Sagar
    Borghaei, Hossein
    Jagannath, Sundar
    Sokol, Lubomir
    Usmani, Saad Z.
    de Velde, Helgi van
    Qin, Xiang
    Puchalski, Thomas A.
    Hall, Brett
    Reddy, Manjula
    Qi, Ming
    van Rhee, Frits
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3659 - 3670
12345